By using organoids, “we can show that for a particular patient subset, for a particular drug, we can do better than the current selection criteria,” stated Else Driehuis, PhD.
The approach combined deep molecular profiling with comprehensive drug sensitivity testing for patients where standard therapy alternatives had been exhausted.
A recently FDA-recognized somatic cancer database organizes tumor genomic profiling and cancer drugs into levels of clinical evidence that can be used by hospital and oncology leaders.
Comprehensive assessment of young adult tumors across multiple cancer types reveals age-related cancer genetics that are important to treatment decisions.
Renewed interest in abandoned drugs for specific subsegments of certain healthcare populations could lead to new personalized treatments for cancer and other chronic diseases.
Researchers have found that cancer cells have different states in which different sets of genes are expressed, influencing what drugs will be effective for those cells given that specific point in time.
Researchers are exploring the many diagnostic possibilities of metabolomics. This new Oxford University study demonstrates value in metastatic cancer detection, using a simple blood test.
New Metabolomics Test Developed by Oxford Enables Noninvasive Diagnosis of Cancer Spread Read More »
Hospital, oncology, and pulmonology leaders will benefit from following the research that builds on this innovative study and the treatments that may emerge.
Researchers questioned what distinguishes mutations in terms of clinical relevance, the goal to identify genes responsible for the spread of cancer cells.
Billionaire funds particle accelerator technology that saved his life, enabling Michigan State University to provide precision medicine radiopharmaceutical treatments.
